Previous close | 7.80 |
Open | 5.19 |
Bid | 3.80 x 200 |
Ask | 6.46 x 200 |
Day's range | 5.00 - 5.39 |
52-week range | 5.00 - 13.49 |
Volume | |
Avg. volume | 76,929 |
Market cap | 1.853B |
Beta (5Y monthly) | 1.11 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORMAGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILESTONE AND ROYALTY PAYMENTS TO EVOTEC BASED ON SUCCESS OF OVERALL PROGRAMS HAMBURG, Germany and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) an